Citigroup Lowers ACADIA Pharmaceuticals (NASDAQ:ACAD) Price Target to $32.00

Key Points

• Citigroup cut its price target on ACADIA Pharmaceuticals from $33 to $32 while keeping a buy rating, implying about 42.9% upside from the prior close.
• ACADIA recently reported Q1 earnings of $0.02 per share and revenue of $268.1 million, both below estimates, though revenue still grew 9.7% year over year and the company reaffirmed its 2026 guidance.
• Analyst sentiment remains generally positive, with an average Moderate Buy rating and a consensus price target of $31; however, several analysts have recently tweaked targets and forecasts, reflecting some caution around near-term profitability.

ACADIA Pharmaceuticals (NASDAQ:ACAD - Get Free Report) had its price target reduced by equities research analysts at Citigroup from $33.00 to $32.00 in a note issued to investors on Friday,Benzinga reports. The brokerage currently has a "buy" rating on the biopharmaceutical company's stock. Citigroup's target price suggests a potential upside of 42.86% from the company's previous close.

ACAD has been the subject of several other reports. Mizuho raised ACADIA Pharmaceuticals from a "neutral" rating to an "outperform" rating and increased their price objective for the company from $29.00 to $35.00 in a report on Monday, February 23rd. Bank of America raised ACADIA Pharmaceuticals from a "neutral" rating to a "buy" rating and set a $29.00 price objective for the company in a report on Wednesday, March 25th. HC Wainwright reissued a "buy" rating and set a $37.00 price objective on shares of ACADIA Pharmaceuticals in a report on Tuesday, February 3rd. Oppenheimer reissued a "market perform" rating on shares of ACADIA Pharmaceuticals in a report on Friday, February 6th. Finally, Royal Bank Of Canada dropped their target price on ACADIA Pharmaceuticals from $31.00 to $30.00 and set an "outperform" rating on the stock in a research report on Thursday, February 26th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $31.00.

ACADIA Pharmaceuticals Stock Performance

Shares of ACADIA Pharmaceuticals stock traded down $0.16 on Friday, hitting $22.40. The company had a trading volume of 2,081,199 shares, compared to its average volume of 1,726,507. The stock has a market capitalization of $3.84 billion, a price-to-earnings ratio of 10.18, a P/E/G ratio of 22.40 and a beta of 0.86. ACADIA Pharmaceuticals has a 1 year low of $16.76 and a 1 year high of $28.35. The stock has a 50 day moving average of $22.06 and a 200-day moving average of $23.90.

ACADIA Pharmaceuticals (NASDAQ:ACAD - Get Free Report) last released its earnings results on Wednesday, May 6th. The biopharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.04 by ($0.02). The business had revenue of $268.10 million during the quarter, compared to the consensus estimate of $280.25 million. ACADIA Pharmaceuticals had a net margin of 34.30% and a return on equity of 10.23%. The business's revenue was up 9.7% on a year-over-year basis. During the same period in the prior year, the company earned $0.11 earnings per share. Equities analysts anticipate that ACADIA Pharmaceuticals will post 0.45 earnings per share for the current year.

Insiders Place Their Bets

In other ACADIA Pharmaceuticals news, EVP Jennifer J. Rhodes sold 6,950 shares of the stock in a transaction on Monday, February 9th. The stock was sold at an average price of $23.38, for a total transaction of $162,491.00. Following the sale, the executive vice president owned 7,609 shares in the company, valued at $177,898.42. This represents a 47.74% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Mark C. Schneyer sold 3,506 shares of the stock in a transaction on Monday, May 4th. The stock was sold at an average price of $21.79, for a total value of $76,395.74. Following the sale, the executive vice president owned 66,145 shares in the company, valued at approximately $1,441,299.55. This represents a 5.03% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 15,527 shares of company stock worth $350,917 over the last 90 days. Corporate insiders own 26.20% of the company's stock.

Institutional Investors Weigh In On ACADIA Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in ACAD. Braidwell LP purchased a new stake in shares of ACADIA Pharmaceuticals in the third quarter worth $50,760,000. Norges Bank purchased a new stake in shares of ACADIA Pharmaceuticals in the fourth quarter worth $40,266,000. Millennium Management LLC raised its position in shares of ACADIA Pharmaceuticals by 2,052.1% in the third quarter. Millennium Management LLC now owns 1,483,235 shares of the biopharmaceutical company's stock worth $31,652,000 after buying an additional 1,414,315 shares in the last quarter. Arrowstreet Capital Limited Partnership raised its position in shares of ACADIA Pharmaceuticals by 390.1% in the third quarter. Arrowstreet Capital Limited Partnership now owns 1,648,864 shares of the biopharmaceutical company's stock worth $35,187,000 after buying an additional 1,312,426 shares in the last quarter. Finally, Logos Global Management LP purchased a new stake in shares of ACADIA Pharmaceuticals in the fourth quarter worth $22,704,000. Hedge funds and other institutional investors own 96.71% of the company's stock.

Key Stories Impacting ACADIA Pharmaceuticals

Here are the key news stories impacting ACADIA Pharmaceuticals this week:

• Neutral Sentiment: ACADIA reported Q1 2026 earnings of $0.02 per share, below the $0.04 consensus, while revenue of $268.1 million also missed estimates. The company did still post 9.7% year-over-year revenue growth and reaffirmed its 2026 guidance. Acadia Pharmaceuticals Reports First Quarter 2026 Financial Results and Reaffirms 2026 Financial Guidance
• Neutral Sentiment: HC Wainwright kept a Buy rating and $37 price target, but trimmed several forward EPS estimates for ACADIA, including FY2026 to $0.37 from $0.46 and Q3 2026 to $0.13 from $0.16, reflecting a slightly more cautious outlook. Analysts Offer Insights on Healthcare Companies: Kissei Pharmaceutical Co (OtherKSPHF), Recursion Pharmaceuticals (RXRX) and ACADIA Pharmaceuticals (ACAD)
• Neutral Sentiment: The firm also lowered longer-term earnings forecasts for FY2027, FY2028, FY2029 and FY2030, but the reductions were modest and the analyst still sees substantial profit growth over time.
• Negative Sentiment: The latest earnings miss and the analyst estimate cuts likely reinforce concerns that near-term profitability may be more uneven than investors expected, which can weigh on the stock. ACAD Q1 Earnings & Revenues Miss Estimates Despite Y/Y Sales Growth

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders. Established in 1993 and headquartered in San Diego, California, ACADIA's research centers concentrate on conditions with significant unmet medical needs, including Parkinson's disease psychosis, Alzheimer's disease psychosis, and schizophrenia. The company utilizes a range of scientific platforms, including selective receptor modulation and precision-targeted compounds, to advance its portfolio of small-molecule therapeutics.

The company's flagship product, NUPLAZID® (pimavanserin), received U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.